US FDA Rare Disease Innovation Hub’s Goals Align With Trump, Leader Says

 
• By Sue Sutter

The hub’s goals of efficiency, centralization and coordination fit with the Trump Administration’s current focus for the FDA, Amy Comstock Rick, director of strategic coalitions, told the Biopharma Congress.

Cars in a row
The Rare Disease Innovation Hub is focused on driving consistency between CBER and CDER decisions. (Shutterstock)

More from Rare Diseases

More from Agency Leadership